Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619599CT.gov A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | — | Not Yet Recruiting | — | — | — |
NCT07639242CT.gov Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07017829CT.gov GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07222566CT.gov Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06822543CT.gov A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | — | Recruiting | — | — | — |
NCT05879484CT.gov Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | — | Withdrawn | — | — | — |
NCT06731270CT.gov Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | — | Recruiting | — | — | — |
NCT06618287CT.gov A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06698042CT.gov A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | — | Active Not Recruiting | — | — | — |
Show 64 more trialsShow fewer
NCT06644768CT.gov A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06572722CT.gov Perioperative Immunotherapy for NSCLC (ECTOP-1030) | — | Withdrawn | — | — | — |
NCT06538012CT.gov TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer | — | Recruiting | — | — | — |
NCT06219174CT.gov Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) | — | Suspended | — | — | — |
NCT06096844CT.gov Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | — | Recruiting | — | — | — |
NCT06343402CT.gov Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05872867CT.gov Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | — | Unknown | — | — | — |
NCT06055465CT.gov Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06140407CT.gov Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT06162221CT.gov Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | — | Recruiting | — | — | — |
NCT05887492CT.gov Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT05860296CT.gov Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | — | Terminated | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT05570825CT.gov SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05633602CT.gov Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study | — | Active Not Recruiting | — | — | — |
NCT05431582CT.gov Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | — | Withdrawn | — | — | — |
NCT05609578CT.gov Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT05493566CT.gov Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05572684CT.gov A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04964960CT.gov Pembro+Chemo in Brain Mets | — | Terminated | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05096663CT.gov Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT05060432CT.gov Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04216316CT.gov Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04736173CT.gov Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04533451CT.gov Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT04107168CT.gov Microbiome Immunotherapy Toxicity and Response Evaluation | — | Unknown | — | — | — |
NCT04120454CT.gov Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT04267848CT.gov Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | — | Recruiting | — | — | — |
NCT04860076CT.gov Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors | — | Unknown | — | — | — |
NCT04340882CT.gov Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade | — | Active Not Recruiting | — | — | — |
NCT04061590CT.gov Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04396457CT.gov Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | — | Unknown | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04027946CT.gov LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03546361CT.gov CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03867175CT.gov Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03971474CT.gov Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | — | Completed | — | — | — |
NCT03793179CT.gov Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03846310CT.gov A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | — | Completed | — | — | — |
NCT03634241CT.gov Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | — | Completed | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03526887CT.gov Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC | — | Completed | — | — | — |
NCT03380871CT.gov A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | — | Completed | — | — | — |
NCT03233724CT.gov Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | — | Terminated | — | — | — |
NCT03225664CT.gov Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | — | Active Not Recruiting | — | — | — |
NCT03322566CT.gov A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | — | Completed | — | — | — |
NCT03322540CT.gov Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | — | Completed | — | — | — |
NCT03184571CT.gov Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03220477CT.gov Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. | — | Active Not Recruiting | — | — | — |
NCT02733250CT.gov Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02955290CT.gov CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02903914CT.gov Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02638090CT.gov Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT02393248CT.gov Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | — | Terminated | — | — | — |
NCT02194738CT.gov Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT00011921CT.gov Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | City of Hope Medical Center | P3 | BB · 64 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epirubicin in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/epirubicin-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →